Analysts forecast that Horizon Pharma PLC (NASDAQ:HZNP) will report sales of $254.14 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Horizon Pharma PLC’s earnings, with estimates ranging from $249.55 million to $258.72 million. Horizon Pharma PLC posted sales of $208.70 million during the same quarter last year, which would indicate a positive year over year growth rate of 21.8%. The firm is scheduled to report its next earnings report on Monday, November 6th.

On average, analysts expect that Horizon Pharma PLC will report full year sales of $254.14 million for the current fiscal year, with estimates ranging from $1.02 billion to $1.06 billion. For the next fiscal year, analysts expect that the firm will report sales of $1.07 billion per share, with estimates ranging from $1.05 billion to $1.08 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Horizon Pharma PLC.

Horizon Pharma PLC (NASDAQ:HZNP) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.29. The business had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.56 EPS.

Several analysts have recently issued reports on the stock. UBS AG set a $16.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Wednesday, June 7th. Mizuho restated a “neutral” rating and set a $9.00 target price (down from $10.00) on shares of Horizon Pharma PLC in a research note on Wednesday. BMO Capital Markets restated an “outperform” rating and set a $18.00 target price (up from $17.00) on shares of Horizon Pharma PLC in a research note on Thursday. Zacks Investment Research upgraded shares of Horizon Pharma PLC from a “sell” rating to a “hold” rating in a research note on Friday. Finally, BidaskClub lowered shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Horizon Pharma PLC presently has an average rating of “Buy” and a consensus price target of $19.46.

WARNING: “Analysts Expect Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $254.14 Million” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/12/analysts-expect-horizon-pharma-plc-hznp-will-announce-quarterly-sales-of-254-14-million.html.

Horizon Pharma PLC (NASDAQ:HZNP) opened at 12.08 on Friday. The stock’s market cap is $1.97 billion. The firm’s 50-day moving average is $12.44 and its 200-day moving average is $13.66. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $23.44.

Horizon Pharma PLC declared that its Board of Directors has approved a stock buyback plan on Monday, May 8th that authorizes the company to repurchase 1,000% of outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

A number of institutional investors have recently made changes to their positions in HZNP. American Century Companies Inc. raised its position in shares of Horizon Pharma PLC by 12.4% in the first quarter. American Century Companies Inc. now owns 547,464 shares of the biopharmaceutical company’s stock valued at $8,092,000 after buying an additional 60,356 shares in the last quarter. Searle & CO. bought a new position in shares of Horizon Pharma PLC during the first quarter valued at approximately $781,000. C WorldWide Group Holding A S raised its position in shares of Horizon Pharma PLC by 16.6% in the first quarter. C WorldWide Group Holding A S now owns 330,709 shares of the biopharmaceutical company’s stock valued at $4,888,000 after buying an additional 47,069 shares in the last quarter. Bowling Portfolio Management LLC bought a new position in shares of Horizon Pharma PLC during the first quarter valued at approximately $616,000. Finally, Adams Diversified Equity Fund Inc. raised its position in shares of Horizon Pharma PLC by 57.7% in the first quarter. Adams Diversified Equity Fund Inc. now owns 48,100 shares of the biopharmaceutical company’s stock valued at $711,000 after buying an additional 17,600 shares in the last quarter. Institutional investors own 82.95% of the company’s stock.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Get a free copy of the Zacks research report on Horizon Pharma PLC (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.